Background There is a need for early identification of children with immunoglobulin A nephropathy (IgAN) at risk of progression of kidney disease. Methods Data on 261 young patients [age <23 years; mean follow-up of 4.9 (range 2.5-8.1) years] enrolled in VALIGA, a study designed to validate the Oxford Classification of IgAN, were assessed. Renal biopsies were scored for the presence of mesangial hypercellularity (M1), endocapillary hypercellu larity (E1), segmental glomerulosclerosis (S1), tubular atrophy/interstitial fibrosis (T1-2) (MEST score) and crescents (C1). Progression was assessed as end stage renal disease and/ or a 50 % loss of estimated glomerular filtration rate (eGFR) (combined endpoint) as well as the rate of renal function
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Introduction
IgA nephropathy (IgAN) has variable clinical presentations and different outcomes in both adults and children [1, 2] . In countries with active school screening programs, such as Japan, IgAN is most frequently diagnosed by the detection of asymptomatic hematuria, which is considered to be an in early phase of the disease [3] , whereas these early cases can be missed in most European and North American countries where proteinuria of more than a trace amount is the common indication for diagnosis by renal biopsy [1] . Although the progression of IgAN to end stage renal disease (ESRD) is slower in children than in adults, probably due to the early diagnosis [4, 5] , some pediatric patients do progress to ESRD during childhood and many have slower but relentless progression during adulthood [6] ; hence the urgency for early therapeutic intervention. On the other hand, many childhood cases will never show progression and, importantly, spontaneous remission of mild IgAN has been reported [7] . These observations emphasize the need to determine risk factors for progression of IgAN in children and young adults so that early treatment can be targeted to high-risk individuals to prevent the development of irreversible renal scarring and progressive renal failure [8] .
A number of recent studies in children have addressed the value of clinical and pathology variables to predict the risk of progression of renal disease in IgAN using the Oxford-MEST classification of IgAN [9] [10] [11] ). This classification is based on scores for four pathological features of IgAN: mesangial (M) or endocapillary (E) hypercellularity, segmental glomeru losclerosis (S) and tubular atrophy-interstitial fibrosis (T). All of these published studies included limited numbers of patients and endpoint events [11] [12] [13] [14] [15] [16] , rendering most of the results from the conventional Cox multivariate analysis non-significant [12] [13] [14] .
To investigate risk factors for progression of IgAN in young patients, we took advantage of the cohort gathered by the retrospective European multicenter study performed to validate the Oxford Classification (VALIGA; European Validation Study of the Oxford Classification of IgA Nephropathy) [17] . This study enrolled 1147 patients from 13 European countries who were followed over a median of 4.7 years and included 261 children and young adults. These patients had a broad spectrum of clinical presentation and MEST pathology features. Outcome was assessed in this sub-cohort as ESRD or 50 % loss of estimated glomerular filtration rate (eGFR) (combined endpoint) as well as the rate of renal function decline (slope of eGFR).
Materials and methods
VALIGA was a European multicenter retrospective study of subjects with primary IgAN, with a follow-up >1 year or progression to ESRD in <1 year [17] . A total of 1147 patients were enrolled in VALIGA and followed over a median of 4.7 years. Patients with Henoch-Schönlein nephritis, chronic hepatitis, diabetes or cancer were excluded. Each renal biopsy was centrally re-scored by the pathology review center in Oxford, UK. Clinical and pathology data were sent to the central database in Turin, Italy. Statistical analysis was undertaken in Cosenza and Turin.
Inclusion criteria, clinical dataset and definitions
An exploratory analysis was performed in the VALIGA cohort to evaluate the effect of age at renal biopsy as a continuum on the hazard of the combined event (defined as progression to ESRD and/or 50 % loss of eGFR) using the cubic splines (free knots) function [18] . Age (adjusted for sex, immunosuppressive treatment, baseline proteinuria and eGFR) had a reasonably linear association with the loghazard of the event until 23 years of age, where the function reaches a peak, changing the slope (Fig. 1 ). For this reason we selected 216 young subjects aged <23 years at renal biopsy [of whom 66.6 % were children <18 years)] from the original VALIGA cohort.
In children, eGFR was estimated using the modified Schwartz formula (constant K = 0.55) [19] with a maximum eGFR set at 120 ml/min/1.73 m 2 (17) as the accuracy of eGFR for higher values is low and also as small variations in creatinine can have a disproportionate impact on the rate of renal function decline. In subjects aged 18-23 years at renal biopsy, eGFR was estimated using the four-variable MDRD (Modification of Diet in Renal Disease) formula [20] . Proteinuria was expressed in grams per day in adults or grams per day per 1.73 m 2 in pediatric patients. Mean arterial blood pressure (MAP) was calculated as one-third the pulse pressure [systolic blood pressure -diastolic blood pressure) + diastolic blood pressure]. The MAP in children was standardized to make comparable measurements at different ages [11, 21] . ESRD was defined as an eGFR of <15 ml/min/1.73 m 2 in all patients. Time-averaged proteinuria (TA-proteinuria) and MAP (TA-MAP) were determined for each year of observation [17, 22] .
Corticosteroid/immunosuppressive (CS/IS) treatment was considered as intent to treat regardless of the type or duration of CS and/or other IS drugs. Renin-angiotensin system blockade (RASB) indicated treatment with either angiotensinconverting enzyme inhibitors or angiotensin receptor blockers or both.
All renal biopsies were centrally reviewed and scored according to the Oxford Classification [17] :
Mesangial hypercellularity (M): M0/M1, ≤/>50 % of glomeruli with mesangial hypercellularity Endocapillary hypercellularity (E): E0/E1, absent/present Segmental glomerulosclerosis (S): S0/S1, absent/present Tubular atrophy/interstitial fibrosis (T): T0/T1-2, ≤25/ >25 % of renal biopsy tissue.
In addition, in this cohort crescents (C) were assessed as C0/ C1 (absent/present).
Outcomes
The clinical outcome was the progression to the combined end point. In addition, the annual rate of renal function decline (eGFR slope) was assessed. We considered as a surrogate (17, 23) .
Statistical methods
Normally distributed variables were expressed as the mean ± standard deviation and compared using Student's t test, oneway analysis of variance or Pearson's test. Non-normal variables were expressed as the median and interquartile range (IQR) and compared either by the Mann-Whitney, KruskalWallis, or Spearman's test. Categorical variables were expressed as the number (percentage) and compared using the Pearson χ 2 test. The rate of renal function decline was determined by fitting a straight line through available data for eGFR using the principle of least squares. This was plotted and visually examined for each patient. Obvious outliers were censored. Univariate analysis followed by multiple linear regression was used to determine independent predictors of slope. To allow comparison, we used the same multivariate models from the original Oxford Classification study [9] . Survival analysis using Cox regression was performed to test the association between each pathology finding and the combined event, and logistic regression analysis was used for the eGFR slope.
The survival tree model analysis was assessed to identify the predictive power of histological variables as well as cut-off values for continuous factors identified as predictors, taking into account interactions among pathological and clinical features. Tree models are exploratory techniques for uncovering interactions among factors, which define patient subgroups [24, 25] . As previously described [26] , the binary tree is built by repeatedly splitting the patients into two subgroups. At each iteration, all values of all covariates, including MEST scores, are tested, and the variable and the value identifying the most homogeneous outcome in the resulting pair of subgroups are selected automatically without any intervention of the researcher. These subgroups are then split again until they are sufficiently homogeneous in terms of outcome or contain <10 % of the patients (to avoid extremely small groups). The tree is the representation of this subgroup formation process.
Predictive factors included in the tree models were the pathology variables (M, E, S, T and C), the clinical variables (baseline eGFR, MAP and proteinuria) and the therapy variables (RASB and CS/IS).
To assess the statistical significance of the subgroups identified by tree-based binary models we performed multivariate Cox (in the case of combined event) and logistic (decline in TA-proteinuria) regression analysis based on the outcome to be evaluated. We compared the Cox models using the concordance index (c-index), which is equivalent to the area under the receiving operating curve (AUC).
For all tests a p < 0.05 value was considered to be statistically significant. All the analyses were performed using R (version 3.0.1; The R Foundation for Statistical Computing, Vienna, Austria).
Results

Clinical data and renal pathology features
The study focused on 261 young subjects aged <23 years at renal biopsy (Cohort 1) of whom 174 were children aged <18 years old (sub-Cohort 2) [ Table 1 ]. The subjects investigated were enrolled from all 13 participating European countries in the VALIGA study [17] .
Patients in Cohort 1 (entire study cohort) were 15.27 ± 4.75 years old at renal biopsy and they were followed Sub-Cohort 2 (composed of children aged <18 years) had a mean age of 12.7 ± 3.6 years (only 11/174 children were aged <6 years) and were followed for a median of 4.63 (2.48-7.35) years. TA-proteinuria was 0.56 (0.27-1.02) g/day/1.73 m 2 and TA-MAP was 86.6 ± 8.5 mmHg. During the follow-up RASB and CS/IS therapy were started in 66.6 and 50.5 % of the patients, respectively. No significant differences in clinical data were found between the Cohort 1 and the children in sub-Cohort 2.
According to the Oxford Classification criteria, of the entire group of young subjects aged <23 years (Cohort 1), 25.7 % showed M1 12.3 % E1, 50 % S1, 6.8 % T1-2 and 13.8 % C1. These biopsy findings were similar to those found in the subgroup of young children (sub-Cohort 2), of whom 21.8 % showed M1, 13.8 % E1, 42.5 % S1, 6.3 % T1-2 and 14.9 % C1 (Table 1 ).
In the entire study cohort of young subjects aged <23 years (Cohort 1) the rate of renal function decline was −0.2 (IQR −2.7 to 0.5) ml/min/1.73 m 2 /year (Table 1) ; 23 (8.8 %) patients reached the combined endpoint of ESRD and/or 50 % reduction in eGFR, 14 (5.4 %) developed ESRD, 20 (7.7 %) had a 50 % reduction in eGFR over the follow-up period and 11 patients (4.2 %) had both of the endpoints. The estimated survival from the combined endpoint was 69.4 % [95 % confidence interval (CI) 55.9-86] at 15 years. In the pediatric subCohort 2, 11 (6.3 %) children reached the combined endpoint, 7 (4.0 %) reached ESRD, 8 (4.6 %) had a 50 % loss of initial eGFR and 4 (2.3 %) had both of the endpoints.
Clinico-pathological correlations
Univariate analysis of the clinical and histological data at renal biopsy for both Cohort 1 and sub-Cohort 2 indicated that only age (p < 0.001 and p = 0.007, respectively) and MAP (p = 0.003 and p = 0.031, respectively) were significantly associated with decline in renal function (Table 2) . Multiple linear regression models including TA-proteinuria and TA-MAP predicted an eGFR slope with higher explained variance (R 2 = 0.228, p < 0.0001) ( Table 2) . We investigated the value of the MEST score to predict the rate of eGFR decline as well as the survival to the combined endpoint. In the whole Cohort 1 of patients aged <23 years, the E1 lesion was not predictive of outcome, while M1, S1 and T1-2 were predictive both by uni-and multivariate analyses of survival to the combined event, but not of the rate of renal function decline (Table 3) . No interaction with treatment was detected. In addition, the presence of crescents (C1) was not predictive of survival to the combined endpoint or to progression. When children in sub-Cohort 2 were considered, no MEST score was predictive of progression (eGFR slope or 
Survival tree analysis
Survival tree analysis was performed in the entire Cohort 1 to detect subgroups of patients with survival from the combined event (Fig. 2) . Four subgroups of patients were identified based on survival free from the combined event.
A subgroup of 58 patients with M0 and baseline proteinuria of <0.4 g/day/1.73 m 2 had a 15-year survival of 100 % (Reference Group; Fig. 2A ). The subgroup of 67 young subjects presenting with M1 were found to have the highest risk (Fig. 2D) A second regression tree analysis was developed to look at the MEST score, initial eGFR and the association with different levels of TA-proteinuria (Fig. 3) . Again, the 67 young patients presenting with M1 (Fig. 3E) Both these subgroups showed a follow-up proteinuria that was significantly higher than those patients with M0, an eGFR of ≥89.6 ml/min/ 1.73 m 2 and age of <12.2 years at diagnosis (Fig. 3A) . A third classification survival tree analysis (Fig. 4) was performed on the 154 young subjects presenting with , those who did not receive any IS treatment had a moderate probability of remission (8/30; p = 0.02; Fig. 4d ), while those who were treated with steroid/IS drugs showed a higher remission rate (10/16; Reference Group; 
Discussion
In the present study we used a new statistical approach, namely, survival tree-based modeling [24, 25] to identify combined clinical and histological risk factors for disease progression that is valid for both children and young adults with IgAN. The results confirm the value of the MEST scores in predicting survival to the combined endpoint of ESRD or 50 % loss of eGFR in young subjects aged <23 years enrolled in the VALIGA study and also provide new insights on the prognostic value of the combination of MEST and clinical factors for children aged <18 years.
The variability of outcome in children with IgAN ranges from remission to progression to ESRD [7, 16, 27, 28] , which emphasizes the need to identify clinical and histological risk factors for progression. The original Oxford study included a limited number of children (56 cases from four continents) which was inadequate for direct sub-analysis, but the interaction with age suggested that the predictive value of the MEST score in children was similar to that in adults [11] . Nationallevel or single-center studies from Japan [12] , China [13] and Sweden [14] (enrolling 161, 218 and 90 children, respectively) aimed at validating the predictive value of the Oxford classification in children with IgAN confirmed the value of some-but not all-of the MEST scores by univariate analysis. However, when multivariate Cox regression models were adjusted for data at renal biopsy (eGFR, MAP and proteinuria), no individual feature maintained an independent predictive value, apart from the MEST T lesions in Chinese pediatric patients. The Swedish validation study found significant predictive value for some scores (ME and T) only in models constructed by combining one histological lesion with proteinuria at renal biopsy or at 1-year follow-up. If clinical variables were not added, only models including two histological variables provided significant prediction by multivariate Cox analysis [14] . The Japanese validation study used an endpoint of eGFR of <60 ml/min/1.73 m 2 instead of the combined endpoint adopted in all of the other studies, hence limiting the possibility of comparison. This study reported a significant predictive value for MEST T lesions only in multivariate models, which included two histological variables. The presence of >30 % crescents was significant only in multivariate models including proteinuria at biopsy [12] .
The analysis of 174 VALIGA children (aged <18 years) from 13 European countries, given the broader spectrum and larger numbers of cases, was predicted to more reliably determine the predictive value of the MEST score in children. The initial analysis failed to identify an association between pathological features and the combined outcome or with eGFR decline over time. The children enrolled in VALIGA included mild cases, with minimal proteinuria and acute glomerular lesions, similar to the features noted in the Japanese cohort, in which an early endpoint was used. These lesions are potentially reversible after steroid/immunosuppressive treatment, a treatment given to more than half of the European children. However, no interaction with therapy was detected, possibly due to the limited number of subgroups of treated and untreated children and/or the small number of outcome events. Indeed, the lack of predictive value of the histological lesions by multivariate analysis in almost all of the pediatric studies may be related to inadequate statistical power. In the Japanese cohort the endpoint of eGFR of <60 ml/min/1.73 m 2 was reached in only 4.3 % of children [12] . In the Chinese cohort, the combined endpoint was attained by 12.4 % of children [13] and in the Swedish study, by 18 % of subjects. In our VALIGA pediatric sub-Cohort the combined endpoint was reached in only 11 children (6.3 % of cases). Analysis of the prognostic value and interaction of clinical and pathology risk factors in children may be of limited statistical significance given these reasons. This may be addressed in the future by pooling individual pediatric IgAN databases with adult databases, as recently performed [29] . These considerations were our incentive to test a novel statistical approach using the VALIGA data.
By analyzing the outcome of VALIGA patients according to patient age at renal biopsy, we observed that the hazard of the combined endpoint in both treated and untreated young subjects increased with age until a plateau was reached at 23 years. This may reflect a high capacity of recovery-either spontaneously or due to therapy-in young subjects which seems to change with age. Hence we performed the analysis of combined clinical and pathological risk factors in subjects aged <23 years. We used a new statistical approach, survival tree-based modeling, which offers an unbiased identification of subgroups of young patients with IgAN with particular risk profiles for progression. The accuracy of the newly adopted model proved to be equal to that of previous approaches, as the discrimination of the tree model, indicated by the c-index, was similar to the Cox regression model built with the same covariates. In addition, this analysis allowed the identification of important factors, which combined clinical and pathology variables, associated with the chosen endpoint. Moreover, it suggests it is possible to identify statistically valid predictive cut-off values for continuous variables. For example, instead of pre-defining levels of proteinuria as risk for progression, this tree-based binary analysis automatically calculates the threshold level for the outcome.
We observed that young subjects presenting with M1 or proteinuria at >0.4 g/day/1.73 m 2 are at higher risk for IgAN progression. This risk is higher in patients even with a mild reduction in eGFR of <90 ml/min/1.73 m 2 at the time of renal biopsy. This is the first time that a multivariate analysis has detected a threshold for proteinuria at renal biopsy in association with a reduction in renal function: the combination of these two risk factors could be easily applied in clinical practice.
The tree analysis also provided important data in children aged <16 years with IgAN without mesangial hypercellularity (M0) and well-preserved eGFR (>90 ml/min/1.73 m 2 ), showing this pediatric patient population has a high probability of proteinuria remission during follow-up. Moreover, in this subgroup of children, the benefits of CS/IS therapy reached statistical significance. Again, these results, if confirmed, have important implications for clinical practice.
In conclusion, the tree-based analysis can potentially identify combinations of risk factors in young subjects with IgAN, unbiased from pre-determined cut-off values. This approach could be of value to pediatricians managing IgAN patients.
This study has several limitations that have to be considered (30) . First of all, this is not a purely pediatric data analysis and should be validated on a larger pediatric cohort. The VALIGA data were collected retrospectively and a relevant bias could be related to missing cases not reported because of incomplete data. The choice of therapy was not standardized, drug exposure was not recorded in detail so the impact of dose and duration cannot be assessed. Larger cohorts are needed to derive definite conclusions on clinicopathological risk factors in children with IgAN. However, the limited enrolment rate in each center and the need for long term follow-up present almost insurmountable hurdles for the development of such a prospective multicenter large-scale collaborative study. This new statistical approach, applied to a cohort of young IgAN subjects, offers a previously unexplored means of generating clinically relevant information for physicians caring for patients with IgAN.
